Ligand Pharmaceuticals Incorporated LGND R2KR3KPHARMA
Company Overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Why Investors Should Care
Generates a return on equity of 22.0%, reflecting efficient use of shareholder capital.
Revenue has grown at a 12.8% CAGR over the past five years.
Maintains a net profit margin of 67.9%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $268.09M (+60.4% YoY); net profit $124.45M.
- Trailing 12 Months Year-on-year growth — revenue +33.7%, earnings +825.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.82% |
| 1 Year: | 33.70% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 825.00% |
Stock Price Performance
| 1 Year: | +97.31% |
| 6 Months: | +34.73% |
| 3 Months: | +2.43% |
| 1 Month: | +3.15% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.61 · Neutral
P/E of 31.70 is above the sector median of 25.61 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 22.0%.
- Excellent profit margin of 67.9%.
- Compounding revenue at 12.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LGND Ligand Pharmaceuticals Incorporated R2KR3KPHARMA | 307.82 | 31.70 | $6.14B | 0.00% | 2.69% | 21.96% | 12.82% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 56.16M | 90.04M | 45.66M | 59.59M | 56.16M | 90.04M | 45.66M | 59.59M | 43.48M | 24.99M | 24.81M | 27.00M | 33.16M | 41.42M | 41.85M | 69.99M | 46.59M | 78.85M | 59.69M | 56.40M | 36.52M | 50.13M | 59.22M | 50.38M | 43.98M | 26.37M | 32.87M | 30.98M | 41.53M | 51.81M | 45.33M | 47.63M | 115.46M | 51.72M | 63.69M |
| Operating Income | - | 15.10M | 3.97M | 5.47M | - | 10.22M | 13.02M | 16.49M | - | 37.04M | 70.17M | 23.36M | - | 826.54M | -4.13M | -5.16M | - | 3.79M | 7.10M | 3.75M | - | 4.71M | 45.74M | 15.71M | - | 2.13M | 8.66M | 12.34M | - | 14.21M | -1.98M | 3.08M | 2.99M | -19.10M | 3.14M | -36.22M | 8.44M | 54.93M | 17.37M | 8.59M |
| Net Income | 6.34M | 6.61M | -6.17M | 1.05M | -3.12M | 45.28M | 73.16M | 67.36M | -42.48M | 45.28M | 73.16M | 67.36M | -42.48M | 666.34M | -14.42M | -15.25M | -7.37M | -24.13M | 22.09M | -6.70M | 5.76M | 18.11M | 30.73M | 13.72M | -5.42M | -15.38M | -895.00K | 404.00K | -17.48M | 41.95M | 2.29M | -10.27M | 86.14M | -51.91M | -7.17M | -42.45M | 4.85M | 117.27M | -13.35M | 48.51M |
| Diluted EPS | 0.29 | 0.30 | -0.30 | 0.05 | 0.15 | 1.83 | 2.99 | 2.80 | -2.02 | 1.83 | 2.99 | 2.80 | -2.02 | 31.32 | -0.74 | -0.81 | -0.43 | -1.46 | 1.32 | -0.42 | 0.35 | 1.05 | 1.79 | 0.80 | - | -0.91 | -0.05 | 0.02 | - | 2.33 | 0.13 | -0.59 | 4.75 | -2.88 | -0.39 | -2.21 | 0.24 | 5.68 | -0.67 | 2.22 |
| R&D Expense | - | 4.00M | 4.91M | 5.90M | - | 8.67M | 4.82M | 4.76M | - | 7.41M | 6.13M | 5.48M | - | 11.29M | 12.21M | 13.74M | - | 11.89M | 12.73M | 12.85M | - | 9.05M | 7.48M | 7.43M | 8.15M | 9.18M | 8.47M | 9.24M | 9.20M | 6.66M | 6.85M | 5.53M | 5.97M | 5.35M | 5.67M | 50.09M | 6.57M | 21.02M | 2.15M | 14.67M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.94M | 23.54M | 30.04M | 31.39M | 48.97M | 64.54M | 71.91M | 108.97M | 141.10M | 251.45M | 120.28M | 163.56M | 241.54M | 196.25M | 131.31M | 167.13M | 268.09M |
| Operating Income | -9.97M | -29.30M | -878.00K | 193.00K | 14.94M | 19.63M | 27.33M | 43.88M | 68.08M | 163.73M | 807.08M | 37.50M | 103.85M | 3.04M | 11.94M | -22.61M | 41.00M |
| Net Income | -1.95M | -10.37M | 9.71M | -527.00K | 11.42M | 12.02M | 229.82M | -1.64M | 12.56M | 143.32M | 629.30M | -2.98M | 57.14M | -33.36M | 52.15M | -4.03M | 124.45M |
| Diluted EPS | - | - | 0.49 | -0.03 | 0.55 | 0.56 | 10.83 | -0.08 | 0.53 | 5.96 | 31.85 | -0.18 | 3.31 | -1.98 | 2.94 | -0.22 | 6.13 |
| R&D Expense | 39.87M | 22.07M | 10.29M | 10.79M | 9.27M | 9.75M | 11.01M | 21.22M | 26.89M | 27.86M | 55.91M | 40.50M | 32.10M | 36.08M | 24.54M | 21.43M | 81.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 75.56M | 120.58M | 104.26M | 104.71M | 258.03M | 503.06M | 601.59M | 671.02M | 1.26B | 1.49B | 1.36B | 1.30B | 762.67M | 787.22M | 941.77M | 1.56B |
| Total Equity | -10.37M | 3.74M | -4.85M | 8.19M | 26.48M | 49.61M | 26.32M | 237.28M | 341.29M | 399.79M | 560.91M | 767.23M | 709.52M | 821.16M | 597.49M | 700.91M | 830.44M | 1.02B |
| Cash & Equivalents | 28.75M | 16.03M | 3.35M | 7.04M | 12.38M | 11.64M | 160.20M | 97.43M | 18.75M | 20.62M | 117.16M | 71.54M | 47.62M | 19.52M | 45.01M | 22.95M | 72.31M | 174.93M |
| Long Term Debt | - | - | - | - | 27.50M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 72.06M | 104.05M | 77.78M | 55.10M | 233.62M | 226.15M | 230.73M | 252.37M | 699.89M | 727.68M | 652.76M | 476.43M | 165.18M | 86.30M | 111.33M | 543.42M |
| Current Liabilities | - | - | 33.49M | 43.64M | 35.44M | 28.94M | 22.78M | 222.82M | 227.13M | 238.87M | 82.25M | 17.00M | 100.11M | 41.66M | 98.81M | 16.78M | 37.11M | 37.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -33.80M | -27.07M | -1.17M | 161.00K | 20.69M | 20.57M | 41.73M | 60.73M | 88.57M | 194.06M | -29.34M | 54.59M | 78.80M | 137.85M | 49.58M | 97.05M | 49.36M |
| Investing Cash Flow | 24.77M | 14.54M | -25.13M | 1.26M | -4.97M | -2.03M | -112.86M | -134.41M | -79.18M | -423.27M | 466.92M | 231.65M | 30.52M | 163.62M | -11.68M | -143.66M | -377.32M |
| Financing Cash Flow | -3.69M | -159.00K | 30.00M | 3.92M | -16.46M | 130.03M | 8.36M | -4.99M | -7.52M | 328.58M | -485.17M | -310.55M | -137.76M | -275.99M | -59.95M | 97.14M | 428.22M |
| Capital Expenditure | -522.00K | -70.00K | -78.00K | -595.00K | -377.00K | -6.00K | -93.00K | -1.85M | -2.16M | -887.00K | -2.55M | -4.46M | -8.76M | -17.92M | -3.52M | -1.82M | -452.00K |
| Free Cash Flow | -34.32M | -27.14M | -1.25M | -434.00K | 20.31M | 20.56M | 41.63M | 58.88M | 86.41M | 193.17M | -31.89M | 50.13M | 70.04M | 119.93M | 46.06M | 95.23M | 48.91M |
| Share Buybacks | - | 91.00K | 55.00K | 0 | 0 | 67.95M | 489.00K | 3.90M | 1.97M | 122.87M | 453.05M | 78.00M | 0 | 0 | 0 | 0 | 15.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -25.6% | -124.5% | -2.9% | 0.6% | 30.5% | 30.4% | 38.0% | 40.3% | 48.2% | 65.1% | 671.0% | 22.9% | 43.0% | 1.5% | 9.1% | -13.5% | 15.3% |
| Net Margin % | -5.0% | -44.1% | 32.3% | -1.7% | 23.3% | 18.6% | 319.6% | -1.5% | 8.9% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
| ROE % | -52.0% | 213.9% | 118.7% | -2.0% | 23.0% | 45.7% | 96.9% | -0.5% | 3.1% | 25.6% | 82.0% | -0.4% | 7.0% | -5.6% | 7.4% | -0.5% | 12.2% |
| ROCE % | - | -69.7% | -1.1% | 0.3% | 19.7% | 8.3% | 9.8% | 11.7% | 15.8% | 13.9% | 54.6% | 3.0% | 8.3% | 0.5% | 1.6% | -2.5% | 2.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.56% | 3.10M | $935.91M |
| 2 | Invesco Ltd. | 6.03% | 1.20M | $362.67M |
| 3 | Vanguard Portfolio Management LLC | 5.71% | 1.14M | $343.56M |
| 4 | Jupiter Topco LLC | 5.22% | 1.04M | $314.06M |
| 5 | Vanguard Capital Management LLC | 4.37% | 870.95K | $262.86M |
| 6 | State Street Corporation | 4.15% | 826.54K | $249.46M |
| 7 | FMR, LLC | 3.83% | 762.83K | $230.23M |
| 8 | Franklin Resources, Inc. | 3.77% | 752.04K | $226.97M |
| 9 | Congress Asset Management Co | 3.30% | 658.56K | $198.76M |
| 10 | Geode Capital Management, LLC | 2.95% | 589.02K | $177.77M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LGND
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQWmZKRnNoZ3BoZ2ZiZzM3NWFYMnNha2pCa1pQekN2N1lrZWdrYnhXZjBTeXphSlB4WlRWWm9DbDVQMWM0OHlySS00c0dUU3RCd2o1Ulo2bnlYY2lkUDNNRm1GaV9HS200ZVplWE1aRHN6bHlhNmNoS3BFUUR5SXN4bDg2SUpYQW95bDlkRn…
A partner CEO will discuss a gel being developed for rare conditions at Ligand's investor day. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOdTBXTkwxa0hfY3QybEVHWHl0WFh4TmdGZEJIRkxJUXA5bF9WS1RiWFBjRnhxaFlURm5aWFo4d0UzdTBmS3VIemlmeXk0M1lyNW1iNkk1SWtDbnNfZDRyRTJPN0lNSllzZzFzZXJRQmJFTTlDSEl2R01OSDdERWNFUzc0VXBFQ1BOOFBtYn…
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPaEgyck9rUWYzOG8tSnd1aktJZzRCTnQ3LVN4N2hMdzNTSUpaSXk4Tk9rd01femR2VmpDZWZpWkhSTzdoLXJpQ0ROTjB4MXEwbWkwMHpoYVM0N3hSbzFvOUNPVk5SMS1ES1N1bkowRUc5ZFBpMkM5YVZCSDZaRWQ1ZWJLa3o0dVc0ZUcxeT…
Ligand Pharmaceuticals (LGND) Could Be 9% Undervalued Following Buy Rated Earnings Strength - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPMGcyam81VklibVduNTAwTnF6TXJHOTFQRzdfVTlQYjhWNC1IdWU4ZDByZk1sY0dmbDZFS2xsRldYUnVPTDZGSGNOVm5UZmJ4ekJfVjZHaVc4cGxOUzNKbnlUbnRxbEVXQWs5OHBKVjBINjQwVjQwRWxHRXlVRXBtdURjTEJaMXZmMHRENV…
Ligand Pharma (LGND) Receives a Buy from Bank of America Securities - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOUVV3cmFtWm80SV9JNFRqSGxKaTlkS1JqN3BlNjBvQVRHdzZPSVUyNXVVYUNUODA2VFJGbmZwdUYtbk95OWd3X3J0M3dVWVJmbHFqQzF6YlcyU3Y4VUNXSXhFOFktMmhZeWZkbmt0dHBhOHJ3MlN6OWd6N0xiV3VOcXZDaktzbjdldEk3WE…
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPb05Sck1ZTE1RVVNEMnUwYVVLT2FzanpCQ2JZT0tQYjR1c3hURndLTWdXZk1VWk5jd0t0anVuXzBmNkQ5RnJlaUZGRXB1N2hPZEJHVUJHNWJRUVhOV1pjRG9rNVBoUkl5T1ZQb3RrM1ZnNlpHZlY0SVNwUkhVRG9DdlNZUUt5bkFMZE1reT…
LGND — Frequently Asked Questions
What is the current share price of Ligand Pharmaceuticals Incorporated (LGND)?
As of 2026-10-22 16:30 PDT, Ligand Pharmaceuticals Incorporated (LGND) trades at $307.82 on NasdaqGM. Its 52-week range is $151.08 to $322.61.
What is the market capitalisation of LGND?
Ligand Pharmaceuticals Incorporated (LGND) has a market capitalisation of $6.14B on NasdaqGM.
What is the P/E ratio of LGND?
LGND trades at a trailing price-to-earnings (P/E) ratio of 31.70. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 5.84.
What is the return on equity (ROE) of LGND?
LGND has a return on equity (ROE) of 21.96%. Its return on capital employed (ROCE) is 2.69%.
Is LGND a good stock to buy?
This page provides a data-driven analysis of Ligand Pharmaceuticals Incorporated (LGND), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.